Sam Janes at the Breath Biopsy Conference 2021
KEYNOTE (45 min) - Screening for lung cancer: The SUMMIT study and biomarker integration
The Breath Biopsy Conference 2022 is scheduled for 1st-3rd November. Click the button to express interest in the next Breath Biopsy Conference:
Talk Abstract:
In the UK, only 12.9% of those diagnosed with lung cancer are alive after five years due to 68% of lung cancers being diagnosed at stage III or IV which infers incurable, advanced disease. One-year survival by stage ranges from around 71% for stage I disease to around 14% for stage IV. Early detection is therefore key to improving lung cancer survival.
The SUMMIT study is a clinical trial run in partnership between UCL, UCLH and an American biotech company (GRAIL Inc). It will help to build the evidence base for a screening programme in the UK. The aim for the US company is to develop a blood test (cfDNA) to detect cancer early before symptoms appear. In my talk I will discuss the challenges in delivering a study like SUMMIT. I’ll examine the evidence for CT screening and the difficulties in delivering it at a population level. I’ll then examine the potential for biomarkers to improve the landscape of lung cancer screening.
Speaker Biography:
Sam won an MRC Training Fellowship to perform a PhD and then a post-doctoral period working in the Cancer Research UK Lincoln’s Inn Fields Institute with Fiona Watt working on lung cancer biology. He then moved as an MRC Clinician Scientist to UCL leading a group interested in the role of stem cells in lung cancer pathogenesis and treatment of lung disease using cell therapies. He was awarded a Wellcome Trust Senior Clinical Fellowship in October 2010 to work on novel cell therapies for lung cancers resulting in a DPFS first-in-man award and in 2015 won his Wellcome Senior Fellowship renewal to study the genetic and cellular changes lung cancer pathogenesis. He is the lead of four academic lead randomised clinical trials and most notably recently launched the SUMMIT study, a 12000 participant London-based study examining CT and blood screening for lung and other cancers.
He works as a respiratory consultant at UCLH with a particular interest in lung cancer, mesothelioma, interventional and diagnostic bronchoscopy and early lung cancer detection. He is Head of the Respiratory Research Department at UCL, Vice-Chair of the National ‘Clinical Expert Group’ on Lung Cancer.
The Breath Biopsy Conference 2022 is scheduled for 1st-3rd November. Click the button to express interest in the next Breath Biopsy Conference: